ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that BioTime completed a registered direct offering of 6,530,612 shares to a select group of TASE Indexes and mutual funds. The total proceeds from the share sale were NIS 80 million, or approximately $20.35 million reflecting the current exchange rate, before investment banking fees and offering expense. The demand exceeded the NIS 80 million that the company offered for sale. The sale price was $3.13 per share.
Help employers find you! Check out all the jobs and post your resume.
